Xi Venture Capital was honored with the "Top 10 Future Industry Investment Institutions in China" list by 36Kr
On September 11th, 36Kr released the "Top 10 Future Industry Investment Institutions in China" list for 2025, and Xichuang Capital was honored as one of the top 20 investment institutions in China's life sciences industry.
The 36Kr Venture Capital Research Institute relies on its self built "36Kr Equity Investment Information Website - Online Research System" to collect and research multidimensional evaluation indicators of investment institutions, such as funds, projects, and transactions. After a period of 2 months of research and evaluation, it finally releases the annual list of Chinese industrial investors for 2025.
Xi Venture Capital has long been deeply involved in strategic emerging industries such as biomedicine and medical health, as well as future industries. It has proactively laid out vertical fields and high potential tracks such as innovative drugs, synthetic biology, precision medicine, and high-end medical devices. By building a "patient capital" fund system covering the entire life cycle of enterprises, it continues to increase professional research and value investment in key core areas, helping innovative enterprises cross the growth cycle, promoting technological breakthroughs and commercial applications, empowering the ecological development of the entire life and health industry chain with capital, anchoring future industrial innovation highlands, and accelerating the cultivation and growth of new quality productivity.
About Xi Venture Capital
Xi Venture Capital is a state-owned venture capital institution that integrates seed, angel, entrepreneurship, equity, mergers and acquisitions, and S funds. The company has established a fund system covering the entire life cycle of enterprises, managing a total fund size of over 280 billion yuan, and providing comprehensive support to enterprises that are in line with their development stages; Focusing on strategic emerging industries such as biomedicine, integrated circuits, dual carbon energy conservation, and artificial intelligence, the management fund has invested in over 2000 companies and participated in the cultivation of more than 110 listed companies such as Longda Corporation, New Clean Energy, and Time Angel.
